SynthesisBMC cancer2025
Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) prognosis remains poor in advanced stages. Stereotactic body radiation therapy (SBRT) combined with pharmacological agents (targeted therapies/immunotherapies) represents a promising multimodal strategy, but its efficacy and safety require comprehensive evaluation.
methodsThis meta-analysis included 9 studies (n = 20,812). The adverse event analysis covered the overall adverse event data from 7 studies (n = 583) and grade ≥ 3 adverse events from 4 studies (n = 303). The survival outcome analysis included 9 studies (n = 20,781) and the progression-free survival analysis included 4 studies (n = 424). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were calculated via fixed/random effects models.
resultsCompared with pharmacological agents, SBRT combined with pharmacological agents significantly improved 1-year OS (RR = 1.55, 95% CI:1.40–1.72), 2-year OS (RR = 1.63, 95% CI:1.33–1.99), objective response rate (RR = 1.87, 95% CI:1.52–2.39) and reduced mortality risk (HR = 0.54, 95% CI:0.40–0.72), progression risk (HR = 0.49, 95% CI:0.38–0.63) without increasing overall adverse events (RR = 1.03, 95% CI:0.98–1.09) or grade ≥ 3 toxicities (RR = 1.12, 95% CI:0.92–1.36).
conclusionSBRT combined with pharmacological agents significantly improves survival and tumor response in advanced HCC without increasing overall toxicity. This synergy supports the integration of SBRT into systemic therapy paradigms for HCC.
trial registrationPROSPERO CRD420251040157.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.